PROGRAM CONTACT:
Deirdre Joy

SUMMARY STATEMENT
(Privileged Communication) Release Date: 11/01/2010

Application Number: 1 R21 AI094129-01

Principal Investigators (Listed Alphabetically):
MYLER, PETER JOHN PHD (Contact)
PARSONS, MARILYN PHD

Applicant Organization: SEATTLE BIOMEDICAL RESEARCH INSTITUTE

Review Group: PTHE
Pathogenic Eukaryotes Study Section

Meeting Date: 10/14/2010
Council: JAN 2011
Requested Start: 04/01/2011

RFA/PA: PA10-069
PCC: M93

Project Title: Ribosome profiling of Trypanosoma brucei

SRG Action: Impact/Priority Score: 10
Human Subjects: 10-No human subjects involved
Animal Subjects: 30-Vertebrate animals involved - no SRG concerns noted

<table>
<thead>
<tr>
<th>Project Year</th>
<th>Direct Costs Requested</th>
<th>Estimated Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ADMINISTRATIVE BUDGET NOTE: The budget shown is the requested budget and has not been adjusted to reflect any recommendations made by reviewers. If an award is planned, the costs will be calculated by Institute grants management staff based on the recommendations outlined below in the COMMITTEE BUDGET RECOMMENDATIONS section.

Time has passed since the application was reviewed. This sample may not reflect the latest format for summary statements. NIAID posts new samples periodically: https://www.niaid.nih.gov/grants-contracts/sample-applications

The text from the application is copyrighted. You may use it only for nonprofit educational purposes provided the document remains unchanged and the PI, the grantee organization, and NIAID are credited.

Contact information. If you have any questions, email the NIAID Office of Knowledge and Educational Resources at deaweb@niaid.nih.gov.
RESUME AND SUMMARY OF DISCUSSION: This application seeks to use ribosome profiling technology to identify genes under translational control in the major developmental stages of *Trypanosoma brucei*, the causative agent of African trypanosomiasis. If successful, this work will have a huge impact in our understanding of transcription and post-transcription regulation in a medically important protozoan and provide an important resource for the community working on cell and molecular biology of trypanosomatids. Additional strengths are the track record of productivity of the investigator and co-investigator, which combines achievements in the field of molecular biology of kinetoplastid parasites and genomics, and the clever, cutting edge, and innovative approaches. Overall, this almost flawless and exciting application raises very high enthusiasm.

DESCRIPTION (provided by applicant): *Trypanosoma brucei*, the causative agent of African trypanosomiasis (“sleeping sickness”), causes more than 50,000 deaths annually. Related trypanosomatid pathogens, including *Trypanosoma cruzi* (the causative agent of Chagas’ disease) and numerous *Leishmania* species (which cause a diverse spectrum of visceral, mucocutaneous, and cutaneous disease), cause even more morbidity and mortality worldwide. Each of these parasites undergoes a complex developmental cycle, alternating between mammalian and insect hosts, as well as proliferating and non-proliferating stages. Exactly how trypanosomatid gene expression gives rise to the different phenotypes at each stage is currently not well understood, but the relative contribution of gene-specific transcriptional control is low. Differences in post-transcriptional mRNA processing and stability undoubtedly play major roles but the poor correlation between mRNA and protein abundance during parasite development indicates that translational and/or post-translational controls are also important. This project seeks to globally and quantitatively assess the rate at which each mRNA is actively translated at any particular time by applying a recently-described technology that couples the ability to isolate the specific “footprints” of mRNAs that are occupied by ribosomes (an indicator of translation) with the depth and breadth of next generation sequencing. Aim 1 will establish the ribosome protection technology in *T. brucei*, using readily cultured non-pathogenic insect stage forms. It will optimize conditions for nuclease treatment to preserve mRNA fragments protected by ribosomes and for the generation of unbiased libraries from the RNA samples for next generation sequencing. It will also include maturation of the bioinformatics pipeline to analyze resulting sequence data. Aim 2 will expand into the pathogenic, mammalian stages of the parasite, and identify genes that are regulated at the level of translation during *T. brucei* development in infective as compared to non-infective forms. The proposed work will provide an important new tool for studying trypanosomatid gene expression, yielding a comprehensive view of the role of translational control in *T. brucei* and clues to its mechanisms, as well as new information on the extent of translation of individual gene products, such as potential drug targets. In addition, it should resolve the current debate over the function of the numerous recently identified RNAs that contain only short open-reading frames, and has the potential to identify non-canonical protein-coding open-reading frames, thus significantly enhancing the ongoing genome annotation.

PROJECT NARRATIVE: The parasite *Trypanosoma brucei* causes fatal human African trypanosomiasis (sleeping sickness) and drugs to treat the disease are toxic and facing resistance. Generating new drugs requires knowledge of which proteins are expressed in the disease-causing stages of parasite development. This project will apply a new technology to measure the initial steps of protein synthesis for all genes in the infective as compared to non-infective stages, thereby providing new information on candidate drug targets.

CRITIQUE 1:
Significance: 1
Investigator(s): 1
Innovation: 2
Overall Impact: An excellent application by an established investigator with a long track record of productivity in both the trypanosome field and the field of genomics. The application is nicely written and aims at applying the recently published technique of ribosome profiling to the study of developmental gene control between different stages of *T. brucei*. The application of ribosome profiling coupled with next generation sequence would be (to my knowledge) a first on the trypanosome field. There is no doubt that the proposed research will finally reconcile the well established differences between the transcriptome and proteome of this organism, where it is now widely accepted that the bulk of the control of gene expression occurs at some step after transcription.

1. Significance:
   Strengths
   - The approach will no doubt reveal in a gene specific manner what genes are controlled postranscriptionally vs. those whose expression is controlled postranslationally (for which little is known in trypanosomes)

   Weaknesses
   - It is not clear how significant is to differentiate between stumpy and slender forms given the complications of separating the two forms (see below). This, however, is not a major weakness.

2. Investigator(s):
   Strengths
   - Very productive investigator well versed in the implementation of a wide array of genomic approaches for the study of trypanosomes
   - Excellent collaboration with Dr. Parsons.

   Weaknesses
   - None.

3. Innovation:
   Strengths
   - The application of the ribosome profiling technique/deep sequencing is a first for the field.
   - Clever and cutting edge.

   Weaknesses
   - No significant weaknesses

4. Approach:
   Strengths
   - Well developed rationale
   - Excellent discussion of alternative approaches

   Weaknesses
The only weakness is the difficulty of obtaining sufficiently pure stumpy vs. slender forms. However, either way even the simple comparison of PCF to BSF is exciting enough.

5. Environment:

Strengths
- Excellent

Weaknesses
- None.

Protections for Human Subjects:
Not Applicable (No Human Subjects)

Vertebrate Animals:
Acceptable

Biohazards:
Acceptable

Resource Sharing Plans:
Acceptable

Budget and Period of Support:
Recommend as Requested

CRITIQUE 2:

Significance: 1
Investigator(s): 1
Innovation: 2
Approach: 1
Environment: 1

Overall Impact: The proposed work will examine the ribosome loading on mRNAs in the major developmental stages of the important parasite species *Trypanosoma brucei*. In addition to the medical importance of the system and related organisms, the molecular biology is highly unusual since post-transcriptional gene control is the “rule” in these organisms. The application is by an established pair of investigators with a very strong record of productivity, including in areas involving very large datasets (e.g., genome sequencing). The plan is very clearly written and involves a cutting edge approach that is perfectly suited to the task. A successful outcome will have a very high impact for many investigators in the future. A letter of support from the technique’s developer completes a near flawless application that is perfectly suited to the R21 funding mechanism.

1. Significance:
Strengths

- African trypanosomes are important parasites in their own right as well as being representative of a class of organisms that includes many other pathogens.
- Polycistronic transcription and post-transcriptional regulation occur in kinetoplastid organisms to a degree seen in no other system; hence they are perfect places to learn new things about how such control is affected, in general.
- The work will produce genome-wide data that will be of enormous interest to all investigators working on the cell and molecular biology of these parasites.

Weaknesses

- None

2. Investigator(s):

Strengths

- Drs. Myler and Parsons have over 50 years experience between them working on the cell and molecular biology of kinetoplastid parasites, often in very productive collaboration.
- They have individually been very productive and performed work at the cutting edge of the field.
- They have collaborated with each other on numerous projects with great success.
- Myler has extensive experience leading large, genome-wide efforts (e.g., genome sequencing) that involve exactly the skills needed here, both in terms of personnel and information management (Dr. Myler directs the bioinformatic facility at his institution).
- The method to be used was developed by Dr. Ingolia who has already provided a detailed protocol to the investigators and provides an appropriate letter of support.

Weaknesses

- None

3. Innovation:

Strengths

- This work represents the application of a cutting edge approach to a group of organisms that have not previously been the object of such global analyses.

Weaknesses

- The method was not developed by the investigators and has already been used in other systems (e.g., yeast).

4. Approach:

Strengths

- The protocol is clearly described and follows an entirely logical plan.
- Inclusion of the three major life stages will make for extremely interesting comparisons.
- The potential to discover the role of some tantalizing, novel ORFs (that are extremely small and of unknown function) is well described.
- Enough examples of transcripts that are strongly regulated post-transcriptionally already exist making validation of the data easy to do at an early stage in the experiments.
Excellent bioinformatic analysis

Weaknesses

• None

5. Environment:

Strengths

• Seattle BioMed has a long history of continuous productivity in the field
• The infrastructure necessary to do the work has been well established as a consequence of other genome-wide efforts carried out there
• There are few other places with the track record and resources to make a compelling case for successful execution of this cutting-edge project

Weaknesses

• None

Protections for Human Subjects:

Not Applicable (No Human Subjects)

Vertebrate Animals:

Acceptable

Biohazards:

Acceptable

Resource Sharing Plans:

Unacceptable

• The plans to share the data are incomplete in that it is not stated within what timeframe the data will be made publicly available. Please be specific.

Budget and Period of Support:

Recommend as Requested

Additional Comments to Applicant (Optional):

• A great use of R21 funds! A fantastic scenario would have the investigators comparing profiles from different places in the polysome profiles (e.g., from polysomes consisting of 1, 2, 3, etc. ribosomes) but I accept that this would be technically much more challenging and financially take the work outside the scope of a R21.

CRITIQUE 3:

Significance: 1
Investigator(s): 2
Innovation: 3  
Approach: 1  
Environment: 1  

**Overall Impact:** This is a very strong application that seeks to define the mRNAs that are undergoing translation in *T. brucei*. The strengths are that the investigator and co-investigator are very versed in large scale genomic analysis, have chosen the correct strain (927) that is pleomorphic, have developed a clever way to derive both control and polysome associated mRNAs and will likely uncover a meaningful translational profile for protein synthesizing mRNA in trypanosomes. The weaknesses are that the group does not outline the controls they will use and the 'standard' mRNAs they expect to find. For example, can they use the leishmania data they note that they have already to detect highly regulate proteins that are regulated by efficient translation and not simply mRNA abundance? Thus, the major problem is that there needs to be some validation that the undertaken protocol is working. The group is very strong and the collaboration between Dr. Parsons and Myler will yield useful information.

**THE FOLLOWING RESUME SECTIONS WERE PREPARED BY THE SCIENTIFIC REVIEW OFFICER TO SUMMARIZE THE OUTCOME OF DISCUSSIONS OF THE REVIEW COMMITTEE ON THE FOLLOWING ISSUES:**

**VERTEBRATE ANIMAL (Resume): ACCEPTABLE**

**COMMITTEE BUDGET RECOMMENDATIONS:** The budget was recommended as requested.
### MEETING ROSTER

**Pathogenic Eukaryotes Study Section**  
**Infectious Diseases and Microbiology Integrated Review Group**  
**CENTER FOR SCIENTIFIC REVIEW**  
**PTHE**  
**October 14, 2010 - October 15, 2010**

#### CHAIRPERSON

**KLEIN, BRUCE STEVEN,** MD  
**PROFESSOR**  
**DEPARTMENT OF PEDIATRICS,**  
**MEDICAL MICROBIOLOGY AND IMMUNOLOGY**  
**UNIVERSITY OF WISCONSIN-MADISON**  
**MADISON, WI 53792**

#### MEMBERS

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Department or Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALFONZO, JUAN D,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY</strong></td>
</tr>
<tr>
<td><strong>BELLOFATTO, VIVIAN,</strong> PHD</td>
<td>PROFESSOR, VICE CHAIR FOR RESEARCH</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY AND MOLECULAR GENETICS</strong></td>
</tr>
<tr>
<td><strong>BOOTHROYD, JOHN C,</strong> PHD</td>
<td>PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY</strong></td>
</tr>
<tr>
<td><strong>BOOTHROYD, JOHN C,</strong> PHD</td>
<td>PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY</strong></td>
</tr>
<tr>
<td><strong>CORMACK, BRENDAN PATRICK,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS</strong></td>
</tr>
<tr>
<td><strong>CUI, LIWANG,</strong> PHD</td>
<td>PROFESSOR</td>
<td><strong>DEPARTMENT OF ENTOMOLOGY</strong></td>
</tr>
<tr>
<td><strong>DEEPE, GEORGE S JR,</strong> MD</td>
<td>PROFESSOR</td>
<td><strong>DIVISION OF INFECTIOUS DISEASES</strong></td>
</tr>
<tr>
<td><strong>DEITSCH, KIRK W,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY</strong></td>
</tr>
<tr>
<td><strong>GOLDBERG, DANIEL E,</strong> PHD</td>
<td>PROFESSOR</td>
<td><strong>DEPARTMENT OF MEDICINE</strong></td>
</tr>
<tr>
<td><strong>GREENBERG, ROBERT M,</strong> PHD</td>
<td>RESEARCH ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF PATHOBIOLOGY</strong></td>
</tr>
<tr>
<td><strong>LORENZ, MICHAEL C,</strong> PHD</td>
<td>ASSISTANT PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY</strong></td>
</tr>
<tr>
<td><strong>MORENO, SILVIA N,</strong> PHD</td>
<td>PROFESSOR</td>
<td><strong>DEPARTMENT OF CELLULAR BIOLOGY</strong></td>
</tr>
<tr>
<td><strong>MOYE-ROWLEY, W SCOTT,</strong> PHD</td>
<td>PROFESSOR AND EXECUTIVE ASSOCIATE HEAD</td>
<td><strong>DEPARTMENT OF MOLECULAR PHYSIOLOGY AND BIOPHYSICS</strong></td>
</tr>
<tr>
<td><strong>NIERMAN, WILLIAM CHARLES,</strong> PHD</td>
<td>PROFESSOR</td>
<td><strong>J.GRAIG VENTER INSTITUTE</strong></td>
</tr>
<tr>
<td><strong>NOVERR, MAIRI,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY, AND PARASITOLOGY</strong></td>
</tr>
<tr>
<td><strong>NOVERR, MAIRI,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY, AND PARASITOLOGY</strong></td>
</tr>
<tr>
<td><strong>NOVERR, MAIRI,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY, AND PARASITOLOGY</strong></td>
</tr>
<tr>
<td><strong>NOVERR, MAIRI,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY, AND PARASITOLOGY</strong></td>
</tr>
<tr>
<td><strong>NOVERR, MAIRI,</strong> PHD</td>
<td>ASSOCIATE PROFESSOR</td>
<td><strong>DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY, AND PARASITOLOGY</strong></td>
</tr>
</tbody>
</table>
ZAVALA, FIDEL P, MD
PROFESSOR
DEPARTMENT OF MOLECULAR MICROBIOLOGY
AND IMMUNOLOGY
BLOOMBERG SCHOOL OF PUBLIC HEALTH
JOHNS HOPKINS UNIVERSITY
BALTIMORE, MD 21205

MAIL REVIEWER(S)
FRANCIS, MICHAEL M, PHD
ASSISTANT PROFESSOR
UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
WORCESTER, MA 01605

LEE, CHAO-HUNG, PHD
PROFESSOR
DEPARTMENT OF PATHOLOGY
AND LABORATORY MEDICINE
SCHOOL OF MEDICINE
INDIANA UNIVERSITY
INDIANAPOLIS, IN 46202

LEWIS, WILLIAM, MD
PROFESSOR
DEPARTMENT OF PATHOLOGY
AND LABORATORY MEDICINE
SCHOOL OF MEDICINE
EMORY UNIVERSITY
ATLANTA, GA 30322

PAULSON, ROBERT FRANK, PHD
ASSOCIATE PROFESSOR
DEPARTMENT OF VETERINARY AND BIOMEDICAL
SCIENCES
CENTER FOR MOLECULAR IMMUNOLOGY AND
INFECTIOUS DISEASE
THE PENNSYLVANIA STATE UNIVERSITY
UNIVERSITY PARK, PA 16802

SCHAFFER, WILLIAM R, PHD
PROGRAM LEADER
MRC LABORATORY OF MOLECULAR BIOLOGY
DIVISION OF CELL BIOLOGY
CAMBRIDGE, CB22QH
UNITED KINGDOM

SCIENTIFIC REVIEW ADMINISTRATOR
BOUNDS, TERA, DVM, PHD
SCIENTIFIC REVIEW OFFICER
CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
BETHESDA, MD 20892

GRANTS TECHNICAL ASSISTANT
WASHINGTON, KELLIE L
EXTRAMURAL SUPPORT ASSISTANT
CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
BETHESDA, MD 20892

* Temporary Member. For grant applications, temporary members may participate in the entire meeting or may review only selected applications as needed.

Consultants are required to absent themselves from the room during the review of any application if their presence would constitute or appear to constitute a conflict of interest.